Last reviewed · How we verify
Low dose Oliceridine
Low dose Oliceridine is a Mu-opioid receptor agonist Small molecule drug developed by Nanjing First Hospital, Nanjing Medical University. It is currently FDA-approved for Acute pain management, Postoperative pain.
Low-dose oliceridine is a selective mu-opioid receptor agonist that provides analgesia with potentially reduced adverse effects compared to standard-dose opioids.
Low-dose oliceridine is a selective mu-opioid receptor agonist that provides analgesia with potentially reduced adverse effects compared to standard-dose opioids. Used for Acute pain management, Postoperative pain.
At a glance
| Generic name | Low dose Oliceridine |
|---|---|
| Sponsor | Nanjing First Hospital, Nanjing Medical University |
| Drug class | Mu-opioid receptor agonist |
| Target | Mu-opioid receptor (OPRM1) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Oliceridine binds to mu-opioid receptors in the central and peripheral nervous system to modulate pain signaling. The low-dose formulation is designed to achieve analgesic efficacy while minimizing respiratory depression, constipation, and other opioid-related side effects through biased signaling or reduced systemic exposure.
Approved indications
- Acute pain management
- Postoperative pain
Common side effects
- Nausea
- Dizziness
- Vomiting
- Constipation
- Respiratory depression
Key clinical trials
- Dexmedetomidine-Enhanced PCIA After Lobectomy in Nicotine-Dependent Patients (PHASE4)
- Efficacy and Safety of Oliceridine for Moderate to Severe Acute Pain After Orthopedic Surgery (PHASE4)
- Oliceridine-Enhanced Analgesia and Recovery: A G-Protein Biased μ-Opioid Study (NA)
- 1.Comparison of the Analgesic Effect of Remifentanil Group and Different Dose Groups of Oliceridine in Postoperative Patients Undergoing Cardiac Surgery 2.Exploring the Hemodynamic Effects of Analgesic Regimens With Different Doses of Oliceridine After Cardiac Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Low dose Oliceridine CI brief — competitive landscape report
- Low dose Oliceridine updates RSS · CI watch RSS
- Nanjing First Hospital, Nanjing Medical University portfolio CI
Frequently asked questions about Low dose Oliceridine
What is Low dose Oliceridine?
How does Low dose Oliceridine work?
What is Low dose Oliceridine used for?
Who makes Low dose Oliceridine?
What drug class is Low dose Oliceridine in?
What development phase is Low dose Oliceridine in?
What are the side effects of Low dose Oliceridine?
What does Low dose Oliceridine target?
Related
- Drug class: All Mu-opioid receptor agonist drugs
- Target: All drugs targeting Mu-opioid receptor (OPRM1)
- Manufacturer: Nanjing First Hospital, Nanjing Medical University — full pipeline
- Therapeutic area: All drugs in Pain Management
- Indication: Drugs for Acute pain management
- Indication: Drugs for Postoperative pain
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing